Combined autophagy and proteasome inhibition a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma

Dan T. Vogl, Edward A. Stadtmauer, Kay See Tan, Daniel F. Heitjan, Lisa E. Davis, Laura Pontiggia, Reshma Rangwala, Shengfu Piao, Yunyoung C. Chang, Emma C. Scott, Thomas M. Paul, Charles W. Nichols, David L. Porter, Janeen Kaplan, Gayle Mallon, James E. Bradner, Ravi K. Amaravadi

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

The efficacy of proteasome inhibition for myeloma is limited by therapeutic resistance, which may be mediated by activation of the autophagy pathway as an alternative mechanism of protein degradation. Preclinical studies demonstrate that autophagy inhibition with hydroxychloroquine augments the antimyeloma efficacy of the proteasome inhibitor bortezomib. We conducted a phase I trial combining bortezomib and hydroxychloroquine for relapsed or refractory myeloma. We enrolled 25 patients, including 11 (44%) refractory to prior bortezomib. No protocol-defined dose-limiting toxicities occurred, and we identified a recommended phase 2 dose of hydroxychloroquine 600 mg twice daily with standard doses of bortezomib, at which we observed dose-related gastrointestinal toxicity and cytopenias. Of 22 patients evaluable for response, 3 (14%) had very good partial responses, 3 (14%) had minor responses, and 10 (45%) had a period of stable disease. Electron micrographs of bone marrow plasma cells collected at baseline, after a hydroxychloroquine run-in, and after combined therapy showed therapy-associated increases in autophagic vacuoles, consistent with the combined effects of increased trafficking of misfolded proteins to autophagic vacuoles and inhibition of their degradative capacity. Combined targeting of proteasomal and autophagic protein degradation using bortezomib and hydroxychloroquine is therefore feasible and a potentially useful strategy for improving outcomes in myeloma therapy.

Original languageEnglish (US)
Pages (from-to)1380-1390
Number of pages11
JournalAutophagy
Volume10
Issue number8
DOIs
StatePublished - Jan 1 2014

Fingerprint

Hydroxychloroquine
Autophagy
Proteasome Endopeptidase Complex
Vacuoles
Proteolysis
Proteasome Inhibitors
Protein Transport
Therapeutics
Plasma Cells
Bone Marrow Cells
Bortezomib
Electrons

Keywords

  • Autophagy
  • Myeloma
  • Proteasome

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Combined autophagy and proteasome inhibition a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. / Vogl, Dan T.; Stadtmauer, Edward A.; Tan, Kay See; Heitjan, Daniel F.; Davis, Lisa E.; Pontiggia, Laura; Rangwala, Reshma; Piao, Shengfu; Chang, Yunyoung C.; Scott, Emma C.; Paul, Thomas M.; Nichols, Charles W.; Porter, David L.; Kaplan, Janeen; Mallon, Gayle; Bradner, James E.; Amaravadi, Ravi K.

In: Autophagy, Vol. 10, No. 8, 01.01.2014, p. 1380-1390.

Research output: Contribution to journalArticle

Vogl, DT, Stadtmauer, EA, Tan, KS, Heitjan, DF, Davis, LE, Pontiggia, L, Rangwala, R, Piao, S, Chang, YC, Scott, EC, Paul, TM, Nichols, CW, Porter, DL, Kaplan, J, Mallon, G, Bradner, JE & Amaravadi, RK 2014, 'Combined autophagy and proteasome inhibition a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma', Autophagy, vol. 10, no. 8, pp. 1380-1390. https://doi.org/10.4161/auto.29264
Vogl, Dan T. ; Stadtmauer, Edward A. ; Tan, Kay See ; Heitjan, Daniel F. ; Davis, Lisa E. ; Pontiggia, Laura ; Rangwala, Reshma ; Piao, Shengfu ; Chang, Yunyoung C. ; Scott, Emma C. ; Paul, Thomas M. ; Nichols, Charles W. ; Porter, David L. ; Kaplan, Janeen ; Mallon, Gayle ; Bradner, James E. ; Amaravadi, Ravi K. / Combined autophagy and proteasome inhibition a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. In: Autophagy. 2014 ; Vol. 10, No. 8. pp. 1380-1390.
@article{b0e8b97527984503b9155bfe39b9f98b,
title = "Combined autophagy and proteasome inhibition a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma",
abstract = "The efficacy of proteasome inhibition for myeloma is limited by therapeutic resistance, which may be mediated by activation of the autophagy pathway as an alternative mechanism of protein degradation. Preclinical studies demonstrate that autophagy inhibition with hydroxychloroquine augments the antimyeloma efficacy of the proteasome inhibitor bortezomib. We conducted a phase I trial combining bortezomib and hydroxychloroquine for relapsed or refractory myeloma. We enrolled 25 patients, including 11 (44{\%}) refractory to prior bortezomib. No protocol-defined dose-limiting toxicities occurred, and we identified a recommended phase 2 dose of hydroxychloroquine 600 mg twice daily with standard doses of bortezomib, at which we observed dose-related gastrointestinal toxicity and cytopenias. Of 22 patients evaluable for response, 3 (14{\%}) had very good partial responses, 3 (14{\%}) had minor responses, and 10 (45{\%}) had a period of stable disease. Electron micrographs of bone marrow plasma cells collected at baseline, after a hydroxychloroquine run-in, and after combined therapy showed therapy-associated increases in autophagic vacuoles, consistent with the combined effects of increased trafficking of misfolded proteins to autophagic vacuoles and inhibition of their degradative capacity. Combined targeting of proteasomal and autophagic protein degradation using bortezomib and hydroxychloroquine is therefore feasible and a potentially useful strategy for improving outcomes in myeloma therapy.",
keywords = "Autophagy, Myeloma, Proteasome",
author = "Vogl, {Dan T.} and Stadtmauer, {Edward A.} and Tan, {Kay See} and Heitjan, {Daniel F.} and Davis, {Lisa E.} and Laura Pontiggia and Reshma Rangwala and Shengfu Piao and Chang, {Yunyoung C.} and Scott, {Emma C.} and Paul, {Thomas M.} and Nichols, {Charles W.} and Porter, {David L.} and Janeen Kaplan and Gayle Mallon and Bradner, {James E.} and Amaravadi, {Ravi K.}",
year = "2014",
month = "1",
day = "1",
doi = "10.4161/auto.29264",
language = "English (US)",
volume = "10",
pages = "1380--1390",
journal = "Autophagy",
issn = "1554-8627",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - Combined autophagy and proteasome inhibition a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma

AU - Vogl, Dan T.

AU - Stadtmauer, Edward A.

AU - Tan, Kay See

AU - Heitjan, Daniel F.

AU - Davis, Lisa E.

AU - Pontiggia, Laura

AU - Rangwala, Reshma

AU - Piao, Shengfu

AU - Chang, Yunyoung C.

AU - Scott, Emma C.

AU - Paul, Thomas M.

AU - Nichols, Charles W.

AU - Porter, David L.

AU - Kaplan, Janeen

AU - Mallon, Gayle

AU - Bradner, James E.

AU - Amaravadi, Ravi K.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The efficacy of proteasome inhibition for myeloma is limited by therapeutic resistance, which may be mediated by activation of the autophagy pathway as an alternative mechanism of protein degradation. Preclinical studies demonstrate that autophagy inhibition with hydroxychloroquine augments the antimyeloma efficacy of the proteasome inhibitor bortezomib. We conducted a phase I trial combining bortezomib and hydroxychloroquine for relapsed or refractory myeloma. We enrolled 25 patients, including 11 (44%) refractory to prior bortezomib. No protocol-defined dose-limiting toxicities occurred, and we identified a recommended phase 2 dose of hydroxychloroquine 600 mg twice daily with standard doses of bortezomib, at which we observed dose-related gastrointestinal toxicity and cytopenias. Of 22 patients evaluable for response, 3 (14%) had very good partial responses, 3 (14%) had minor responses, and 10 (45%) had a period of stable disease. Electron micrographs of bone marrow plasma cells collected at baseline, after a hydroxychloroquine run-in, and after combined therapy showed therapy-associated increases in autophagic vacuoles, consistent with the combined effects of increased trafficking of misfolded proteins to autophagic vacuoles and inhibition of their degradative capacity. Combined targeting of proteasomal and autophagic protein degradation using bortezomib and hydroxychloroquine is therefore feasible and a potentially useful strategy for improving outcomes in myeloma therapy.

AB - The efficacy of proteasome inhibition for myeloma is limited by therapeutic resistance, which may be mediated by activation of the autophagy pathway as an alternative mechanism of protein degradation. Preclinical studies demonstrate that autophagy inhibition with hydroxychloroquine augments the antimyeloma efficacy of the proteasome inhibitor bortezomib. We conducted a phase I trial combining bortezomib and hydroxychloroquine for relapsed or refractory myeloma. We enrolled 25 patients, including 11 (44%) refractory to prior bortezomib. No protocol-defined dose-limiting toxicities occurred, and we identified a recommended phase 2 dose of hydroxychloroquine 600 mg twice daily with standard doses of bortezomib, at which we observed dose-related gastrointestinal toxicity and cytopenias. Of 22 patients evaluable for response, 3 (14%) had very good partial responses, 3 (14%) had minor responses, and 10 (45%) had a period of stable disease. Electron micrographs of bone marrow plasma cells collected at baseline, after a hydroxychloroquine run-in, and after combined therapy showed therapy-associated increases in autophagic vacuoles, consistent with the combined effects of increased trafficking of misfolded proteins to autophagic vacuoles and inhibition of their degradative capacity. Combined targeting of proteasomal and autophagic protein degradation using bortezomib and hydroxychloroquine is therefore feasible and a potentially useful strategy for improving outcomes in myeloma therapy.

KW - Autophagy

KW - Myeloma

KW - Proteasome

UR - http://www.scopus.com/inward/record.url?scp=84905494696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905494696&partnerID=8YFLogxK

U2 - 10.4161/auto.29264

DO - 10.4161/auto.29264

M3 - Article

VL - 10

SP - 1380

EP - 1390

JO - Autophagy

JF - Autophagy

SN - 1554-8627

IS - 8

ER -